JP2019531288A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531288A5
JP2019531288A5 JP2019514710A JP2019514710A JP2019531288A5 JP 2019531288 A5 JP2019531288 A5 JP 2019531288A5 JP 2019514710 A JP2019514710 A JP 2019514710A JP 2019514710 A JP2019514710 A JP 2019514710A JP 2019531288 A5 JP2019531288 A5 JP 2019531288A5
Authority
JP
Japan
Prior art keywords
viral vector
composition
replication
functional group
defective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019514710A
Other languages
English (en)
Japanese (ja)
Other versions
JP7051132B2 (ja
JP2019531288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/073370 external-priority patent/WO2018050872A1/en
Publication of JP2019531288A publication Critical patent/JP2019531288A/ja
Publication of JP2019531288A5 publication Critical patent/JP2019531288A5/ja
Application granted granted Critical
Publication of JP7051132B2 publication Critical patent/JP7051132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019514710A 2016-09-16 2017-09-15 ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法 Active JP7051132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16189276 2016-09-16
EP16189276.5 2016-09-16
PCT/EP2017/073370 WO2018050872A1 (en) 2016-09-16 2017-09-15 A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy

Publications (3)

Publication Number Publication Date
JP2019531288A JP2019531288A (ja) 2019-10-31
JP2019531288A5 true JP2019531288A5 (enExample) 2020-07-30
JP7051132B2 JP7051132B2 (ja) 2022-04-11

Family

ID=57083083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514710A Active JP7051132B2 (ja) 2016-09-16 2017-09-15 ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法

Country Status (5)

Country Link
US (2) US11166915B2 (enExample)
EP (1) EP3512939A1 (enExample)
JP (1) JP7051132B2 (enExample)
CN (1) CN109952372A (enExample)
WO (1) WO2018050872A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018050872A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
WO2018050873A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
WO2020023612A1 (en) * 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
KR102058961B1 (ko) 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
KR102288367B1 (ko) 2018-11-15 2021-08-11 주식회사 바이오앱 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법
CN112138153B (zh) * 2019-06-28 2022-08-23 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
CA3180446A1 (en) * 2020-05-28 2021-12-02 Ahmed BESHEER Formulations for viral vectors
EP4598572A1 (en) * 2022-10-04 2025-08-13 Emergent Product Development Gaithersburg Inc. Novel vsv virus formulations
CN117065720B (zh) * 2023-07-21 2025-08-22 湖南新九方科技有限公司 一种热解生物炭吸附材料及其制备方法和应用
WO2025125222A1 (en) * 2023-12-11 2025-06-19 Leukocare Ag Compositions comprising viruses, viral vectors or virus-like particles
CN119548638B (zh) * 2025-01-21 2025-10-24 金宇保灵生物药品有限公司 一种活疫苗耐热保护剂及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718889A1 (de) 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE19508192A1 (de) 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
EP4170024A1 (en) 2004-06-01 2023-04-26 Genzyme Corporation Compositions and methods to prevent aav vector aggregation
PL1778723T3 (pl) 2004-08-17 2013-03-29 Regeneron Pharma Preparaty antagonisty IL-1
AU2006315026B2 (en) 2005-11-21 2012-11-22 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
GB0715723D0 (en) 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
EP2236520A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US9610343B2 (en) * 2009-05-20 2017-04-04 Aeras Global Tb Vaccine Foundation Stable, spray dryed, immunogenic, viral compositions
US8557253B2 (en) 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
CN102188701A (zh) * 2010-03-12 2011-09-21 上海泽润生物科技有限公司 一种磷酸铝佐剂及其制备方法
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
JP5798356B2 (ja) 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
US9453067B2 (en) 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
WO2012177970A1 (en) * 2011-06-24 2012-12-27 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
JP6417217B2 (ja) 2011-06-28 2018-10-31 ロイコケア・アクチェンゲゼルシャフト ウイルスまたは細菌の新規な安定化方法
EP3511336B1 (en) 2011-06-28 2023-06-21 Leukocare Ag Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide
ES2971444T3 (es) 2011-10-11 2024-06-05 F Hoffmann Lar Roche Ag Ensamblaje mejorado de anticuerpos biespecíficos
CA2951856A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
HK1207312A1 (en) 2012-06-25 2016-01-29 新兴产品开发盖瑟斯堡有限公司 Temperature stable vaccine formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CA2926384A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
KR20160030963A (ko) 2013-07-11 2016-03-21 시노팜 타이완 리미티드 황산화 올리고당을 검출하기 위한 분석 방법
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
EP3060247A1 (en) * 2013-10-25 2016-08-31 Leukocare Ag A novel method for the production of stabile vaccines
CN105039358B (zh) * 2013-12-03 2020-02-28 北京康乐卫士生物技术股份有限公司 58型重组人乳头瘤病毒病毒样颗粒及其制备方法
US20180028593A1 (en) 2014-03-21 2018-02-01 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
AU2015357225B2 (en) * 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2018050873A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
JP7170329B2 (ja) 2016-09-16 2022-11-14 ロイコケア・アクチェンゲゼルシャフト 処理中の生物医薬製品の安定化のための新規な方法
WO2018050872A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
WO2018050874A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method of producing a liquid biopharmaceutical drug product

Similar Documents

Publication Publication Date Title
JP2019531288A5 (enExample)
JP2020508648A5 (enExample)
JP2017532966A5 (enExample)
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
JP5307801B2 (ja) 凍結乾燥フォームによる生物活性材料の防腐
JP2014516536A5 (enExample)
EP4253403A2 (en) Zika virus purification
JP2015501840A5 (enExample)
JP2016534034A5 (enExample)
WO2019060454A3 (en) Adeno-associated virus variant capsids and methods of use thereof
JP2018520997A5 (enExample)
JP2019146574A5 (enExample)
JP2015501656A5 (enExample)
JP2020528911A5 (enExample)
JP2016506416A5 (enExample)
JP2014502156A5 (enExample)
JP2019526580A5 (enExample)
JP2019519252A5 (enExample)
JP2014503206A (ja) アデノウイルス血清型26および血清型35のフィロウイルスワクチン
MX2021015465A (es) Vacuna para fiebre porcina africana.
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
JP2019531288A (ja) ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
JP2019506175A5 (enExample)
CN103316356A (zh) 一种重组慢病毒载体制剂
JP2020533411A5 (enExample)